PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Winkler, C. ; Haupt, F. ; Heigermoser, M. ; Zapardiel-Gonzalo, J. ; Ohli, J. ; Faure, T. ; Kalideri, E. ; Hommel, A.* ; Delivani, P.* ; Berner, R.* ; Kordonouri, O.* ; Roloff, F.* ; von dem Berge, T.* ; Lange, K.* ; Oltarzewski, M.* ; Glab, R.* ; Szypowska, A.* ; Snape, M.D.* ; Vatish, M.* ; Todd, J.A.* ; Larsson, H.E.* ; Ramelius, A.* ; Kördel, J.* ; Casteels, K.* ; Paulus, J.* ; Ziegler, A.-G. ; Bonifacio, E.*

Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials-GPPAD-02 study design and first results.

Pediatr. Diabetes 20, 720-727 (2019)
Verlagsversion Postprint Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Primary prevention of type 1 diabetes (T1D) requires intervention in genetically at-risk infants. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has established a screening program, GPPAD-02, that identifies infants with a genetic high risk of T1D, enrolls these into primary prevention trials, and follows the children for beta-cell autoantibodies and diabetes. Genetic testing is offered either at delivery, together with the regular newborn testing, or at a newborn health care visits before the age of 5 months in regions of Germany (Bavaria, Saxony, Lower Saxony), UK (Oxford), Poland (Warsaw), Belgium (Leuven), and Sweden (Region Skane). Seven clinical centers will screen around 330 000 infants. Using a genetic score based on 46 T1D susceptibility single-nucleotide polymorphisms (SNPs) or three SNPS and a first-degree family history for T1D, infants with a high (>10%) genetic risk for developing multiple beta-cell autoantibodies by the age of 6 years are identified. Screening from October 2017 to December 2018 was performed in 50 669 infants. The prevalence of high genetic risk for T1D in these infants was 1.1%. Infants with high genetic risk for T1D are followed up and offered to participate in a randomized controlled trial aiming to prevent beta-cell autoimmunity and T1D by tolerance induction with oral insulin. The GPPAD-02 study provides a unique path to primary prevention of beta-cell autoimmunity in the general population. The eventual benefit to the community, if successful, will be a reduction in the number of children developing beta-cell autoimmunity and T1D.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.347
1.273
13
17
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Beta-cell Autoantibodies ; Genetic Risk For Type 1 Diabetes ; Type 1 Diabetes; Autoantibodies; Children
Sprache englisch
Veröffentlichungsjahr 2019
HGF-Berichtsjahr 2019
ISSN (print) / ISBN 1399-543X
e-ISSN 1399-5448
Zeitschrift Pediatric Diabetes
Quellenangaben Band: 20, Heft: 6, Seiten: 720-727 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research (IDF)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502100-001
DOI 10.1111/pedi.12870
WOS ID WOS:000478602200007
Scopus ID 85067356439
PubMed ID 31192505
Erfassungsdatum 2019-06-25
[➜Korrektur melden]